| 肿瘤合并心房颤动的卒中风险评估及抗凝治疗 |
| |
| 引用本文： | 李子文,刘飞,蔺雅娟,夏云龙.肿瘤合并心房颤动的卒中风险评估及抗凝治疗[J].心血管病学进展,2020(5):472-475. |
| |
| 作者姓名： | 李子文 刘飞 蔺雅娟 夏云龙 |
| |
| 作者单位： | 大连医科大学研究生院;大连医科大学附属第一医院心律失常科 |
| |
| 摘 要： | 肿瘤患者中的心房颤动发病率高于一般人群,肿瘤合并心房颤动时卒中风险亦明显增加,而目前指南并未明确该类患者的卒中及其抗凝相关出血风险的评估,临床仍沿用心房颤动的评估量表,忽略了肿瘤及其治疗等因素而低估了风险。此外,传统抗凝药物因其药物相互作用等原因在肿瘤合并心房颤动患者中应用受限,而新型口服抗凝药物的有效性和安全性相关研究得到了广泛关注。
|
| 关 键 词： | 卒中 出血 抗凝 新型口服抗凝药物 |
Stroke Risk Evaluation and Anticoagulation in Atrial Fibrillation Patients with Cancer |
| |
| LI Ziwen,LIU Fei,LIN Yajuan,XIA Yunlong.Stroke Risk Evaluation and Anticoagulation in Atrial Fibrillation Patients with Cancer[J].Advances in Cardiovascular Diseases,2020(5):472-475. |
| |
| Authors: | LI Ziwen LIU Fei LIN Yajuan XIA Yunlong |
| |
| Institution: | (Graduate School,Dalian Medical University,Dalian 116000,Liaoning,China;Department of Arrhythmia,The First Affiliated Hospital of Dalian Medical University,Dalian 116000,Liaoning,China) |
| |
| Abstract: | The incidence rate of atrial fibrillation in cancer patients is higher than that in the general population,and the risk of stroke also significantly increased in patients with cancer and atrial fibrillation.The current guidelines do not define the risk of stroke and anticoagulation related bleeding in such patients,and the evaluation scale of atrial fibrillation is still used in clinical practice,underestimating the risk for ignoring the cancer and its treatment.Furthermore,the application of traditional anticoagulants in cancer patients with atrial fibrillation is limited because of their drug interactions,and the research on the efficacy and safety of new oral anticoagulants have been widely concerned. |
| |
| Keywords: | Stroke Bleeding Anticoagulation New oral anticoagulants |
| 本文献已被 CNKI 维普 等数据库收录！ |
|
